Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
July 20 2023 - 7:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company leveraging its extensive virology
expertise to develop novel therapeutics that target specific viral
diseases, today announced that it has scheduled its second quarter
2023 financial results and corporate update for Thursday, August 3,
2023. The schedule for the press release and conference
call/webcast are as follows:
• |
Q2/2023 Press Release: |
Thursday, August 3, 2023 at 7:30 a.m. ET |
• |
Q2/2023 Conference Call/Webcast: |
Thursday, August 3, 2023 at 8:45 a.m. ET |
To dial-in for the conference call by phone,
please register using the following link: Registration Link. A live
webcast of the conference call can be accessed through the
Investors section of Arbutus' website at www.arbutusbio.com.
An archived webcast will be available on the
Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to develop novel therapeutics that target
specific viral diseases. Our current focus areas include Hepatitis
B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV,
we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and
an oral RNA destabilizer to potentially identify a combination
regimen with the aim of providing a functional cure for patients
with chronic HBV by suppressing viral replication, reducing surface
antigen and reawakening the immune system. We believe our lead
compound, AB-729, is the only RNAi therapeutic with evidence of
immune re-awakening. AB-729 is currently being evaluated in
multiple phase 2 clinical trials. We also have an ongoing drug
discovery and development program directed to identifying novel,
orally active agents for treating coronaviruses, (including
SARS-CoV-2), for which we have nominated a compound and have begun
IND-enabling pre-clinical studies. In addition, we are also
exploring oncology applications for our internal PD-L1 portfolio.
For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. CaperelliVice President, Investor RelationsPhone:
215-206-1822Email: lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2024 to May 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From May 2023 to May 2024